Therefore, when assessing CHI3L1’s role of the efficacy of therapeutic interventions, it is essential to account for these limitations and compliment animal studies using huma cells, tissues (e.g., cancer cell lines), and clinical specimens. This evidence concerns the gene CHI3L1 and cancer.